Subscribe
Models
Our Products
Featured Catalog
Humanized Mouse Models
Tool Mice
Custom Model Services
Preclinical Solutions
Resources
About Us
huRHO-P347S Mouse
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
huRHO-P347S Mouse
Product Name
huRHO-P347S Mouse
Product ID
C002130
Strain Name
C57BL/6Cya-Rhotm5(hRHO*P347S)/Cya
Background
C57BL/6Cya
Status
When using this mouse strain in a publication, please cite “huRHO-P347S Mouse (Catalog C002130) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
Standard products are sold as live mice derived from cryorecovery or expansion. Frozen materials are available upon request. Pricing and lead times depend on real-time inventory.
Basic Information
Related Resource
Basic Information
Gene Name
RHO
Gene Alias
RP4, OPN2, CSNBAD1
NCBI ID
Chromosome
Chr 3 (Human)
MGI ID
Datasheet
Strain Description
Retinitis pigmentosa (RP) is a hereditary retinal disease with a global prevalence of approximately 1:5000-1:3000. RP is highly clinically and genetically heterogeneous, with mutations in the rhodopsin (RHO) gene causing approximately 25% of dominant RP [1]. The rhodopsin encoded by the RHO gene is closely associated with visual light transduction and GPCR downstream signals. Rhodopsin is essential for the transmission of light signals in the process of vision formation. Most RHO mutations lead to high levels of rhodopsin expression in photoreceptor cells, causing many mutant proteins to be abnormally located and aggregated in cells. This results in the apoptosis of photoreceptor cells, which cannot perform normal light signal transduction functions. Additionally, mutations in the RHO gene are associated with congenital stationary night blindness (CSNB) [2-6]. The P347S (Pro347Ser) mutation is located in the C-terminal cytoplasmic tail of the rhodopsin (RHO) protein. It may impair the polarized transport and localization of rhodopsin to rod photoreceptor outer segments, resulting in abnormal distribution of some mutant proteins and the accumulation of extracellular vesicles, ultimately leading to progressive photoreceptor degeneration. P347S is a reported pathogenic mutation associated with autosomal dominant retinitis pigmentosa (adRP) [7-9].
The huRHO-P347S mouse was generated using gene-editing technology by replacing the sequence from the start codon to the region downstream of exon 5 of the mouse Rho gene with the corresponding human RHO gene sequence and introducing the p.P347S (CCG to TCG) point mutation into exon 5 of the human RHO gene. This model can be used to investigate the pathogenesis and progression of RHO mutation-associated autosomal dominant retinitis pigmentosa (adRP) and to evaluate potential therapeutic strategies in preclinical studies. Based on the self-developed technological innovation of TurboKnockout fusion BAC recombination, Cyagen can also provide customized services for different point mutations to meet the needs of a wide range of R&D personnel regarding the pharmacodynamics of retinitis pigmentosa (RP) and other preclinical needs.
Reference
Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006 Nov 18;368(9549):1795-809.
Meng D, Ragi SD, Tsang SH. Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa. Mol Ther. 2020 Oct 7;28(10):2139-2149.
Sakami S, Maeda T, Bereta G, Okano K, Golczak M, Sumaroka A, Roman AJ, Cideciyan AV, Jacobson SG, Palczewski K. Probing mechanisms of photoreceptor degeneration in a new mouse model of the common form of autosomal dominant retinitis pigmentosa due to P23H opsin mutations. J Biol Chem. 2011 Mar 25;286(12):10551-67.
Dryja T P, Mcgee T L, Reichel E, et al. A point mutation of the rhodopsin gene in one form of retinitispigmentosa[J]. Nature, 1990, 343(6256):364-366.
Zhang X, Fu W, Pang C P, et al. Screening for point mutations in rhodopsin gene among one hundred Chinese patients with retinitis pigmentosa[J]. Chinese Journal of Medical Genetics, 2002, 19(6):463-466.
Gamundi M J, Hernan I, Muntanyola M, et al. Transcriptional expression of cis-acting and trans-acting splicing mutations cause autosomal dominant retinitis pigmentosa[J]. Human Mutation, 2008.
Li T, Snyder WK, Olsson JE, Dryja TP. Transgenic mice carrying the dominant rhodopsin mutation P347S: evidence for defective vectorial transport of rhodopsin to the outer segments. Proceedings of the National Academy of Sciences. 1996;93(24):14176–14181.
Athanasiou D, Aguila M, Bellingham J, Li W, McCulley C, Reeves PJ, Cheetham ME. The molecular and cellular basis of rhodopsin retinitis pigmentosa reveals potential strategies for therapy. Prog Retin Eye Res. 2018 Jan;62:1-23.
Bonilha VL, Rayborn ME, Bell BA, Marino MJ, Beight CD, Pauer GJ, Traboulsi EI, Hollyfield JG, Hagstrom SA. Retinal histopathology in eyes from patients with autosomal dominant retinitis pigmentosa caused by rhodopsin mutations. Graefes Arch Clin Exp Ophthalmol. 2015 Dec;253(12):2161-9.
Strain Strategy
The sequence from the start codon to the region downstream of exon 5 of the mouse Rho gene was replaced with the corresponding human RHO gene sequence, and the p.P347S (CCG to TCG) point mutation was introduced into exon 5 of the human RHO gene.

Figure 1. Diagram of the gene editing strategy for the generation of huRHO-P347S mice.
Application Area
Research on retinitis pigmentosa (RP);
Research on other retinal diseases.
Related Resource
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
